U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. Postmarket Drug Safety Information for Patients and Providers
  5. Information on Fenofibric Acid (marketed as Trilipix)
  1. Postmarket Drug Safety Information for Patients and Providers

Information on Fenofibric Acid (marketed as Trilipix)

Trilipix is a prescription medicine used to treat cholesterol in the blood by lowering low-density lipoprotein (LDL) cholesterol ("bad cholesterol"), and increasing the high-density lipoprotein (HDL) cholesterol ("good cholesterol").  It can be used to lower very high levels of fat (triglycerides) in the blood to help reduce the risk for pancreatitis. Also, it can be used in combination with other cholesterol-lowering medicines called statins in patients at high risk for cardiovascular disease.

 

This information reflects FDA’s current analysis of data available to FDA concerning this drug. FDA is not advising practitioners to discontinue prescribing the product. FDA intends to update this sheet when additional information or analyses become available.


Adverse reactions or quality problems experienced with the use of this Product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax, using the contact information at the bottom of this sheet.

 

 

Related Information

Labeling and Regulatory History from Drugs@FDA

Back to Top